| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |